SecSonar.com

Kura Oncology, Inc. (KURA)

Kura Oncology, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Kura Oncology, Inc. (KURA) is a Biotechnology company based in US with a market capitalization of $900.2M. Free cash flow was negative at -$70.7M. This page tracks KURA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 192 employees · IPO Sep 16, 2015

Valuation

Valuation & price

$9.22 · as of May 17, 2026 · -24.1% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

5.17

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$12.14$8.84$5.54Jul 25Dec 25Jul 26Jul 7, 25$5.68Jul 9, 25$6.16Jul 11, 25$6.28Jul 15, 25$6.13Jul 17, 25$6.60Jul 21, 25$6.47Jul 23, 25$6.44Jul 25, 25$6.23Jul 29, 25$6.37Jul 31, 25$6.05Aug 4, 25$6.32Aug 6, 25$6.03Aug 11, 25$5.54Aug 13, 25$6.49Aug 15, 25$7.34Aug 19, 25$7.19Aug 21, 25$7.44Aug 25, 25$7.65Aug 27, 25$7.86Aug 29, 25$7.90Sep 3, 25$8.43Sep 5, 25$8.22Sep 9, 25$8.01Sep 11, 25$8.82Sep 16, 25$8.35Sep 18, 25$8.44Sep 22, 25$8.09Sep 24, 25$8.38Sep 26, 25$9.05Sep 30, 25$8.85Oct 2, 25$9.14Oct 6, 25$9.80Oct 8, 25$10.08Oct 10, 25$9.85Oct 14, 25$9.62Oct 16, 25$10.13Oct 21, 25$9.58Oct 23, 25$9.10Oct 27, 25$11.04Oct 29, 25$10.26Oct 31, 25$10.27Nov 4, 25$9.96Nov 6, 25$10.16Nov 10, 25$10.32Nov 12, 25$10.68Nov 14, 25$11.21Nov 18, 25$11.08Nov 20, 25$10.98Nov 25, 25$11.60Nov 28, 25$12.14Dec 2, 25$11.13Dec 4, 25$11.98Dec 8, 25$11.64Dec 10, 25$10.74Dec 12, 25$10.22Dec 16, 25$10.63Dec 18, 25$9.85Dec 22, 25$11.27Dec 24, 25$11.06Dec 29, 25$10.45Jan 2, 26$10.34Jan 6, 26$9.54Jan 8, 26$9.55Jan 12, 26$9.17Jan 14, 26$9.36Jan 16, 26$8.46Jan 21, 26$8.72Jan 23, 26$8.63Jan 27, 26$8.47Jan 29, 26$8.22Feb 2, 26$8.27Feb 4, 26$8.07Feb 9, 26$7.77Feb 11, 26$7.84Feb 13, 26$8.31Feb 18, 26$8.49Feb 20, 26$8.46Feb 24, 26$8.38Feb 26, 26$8.65Mar 2, 26$8.68Mar 4, 26$8.55Mar 6, 26$8.96Mar 10, 26$9.26Mar 12, 26$8.84Mar 17, 26$8.58Mar 19, 26$8.43Mar 23, 26$8.32Mar 25, 26$8.55Mar 27, 26$7.74Mar 31, 26$8.13Apr 2, 26$8.61Apr 7, 26$8.82Apr 9, 26$8.85Apr 13, 26$8.72Apr 15, 26$9.05Apr 17, 26$9.68Apr 22, 26$9.53Apr 24, 26$9.26Apr 28, 26$8.83Apr 30, 26$8.83May 4, 26$9.25May 6, 26$9.56May 8, 26$9.42May 12, 26$9.68May 14, 26$9.74May 18, 26$9.20May 20, 26$10.34May 22, 26$11.25May 28, 26$9.97Jun 1, 26$9.04Jun 3, 26$8.65Jun 5, 26$8.74Jun 9, 26$8.81Jun 11, 26$8.86Jun 15, 26$9.54Jun 17, 26$9.57Jun 22, 26$10.36Jun 24, 26$10.62Jun 26, 26$10.90Jul 2, 26$10.73
$5.5452-week range$12.14
Loading valuation history…

Fundamentals

Key fundamentals

$900.2M

Market cap

—

Revenue growth (YoY)

99.9%

Gross margin

-$70.7M

Free cash flow (USD)

-$646.8M

Net debt

Net cash position

1.8%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$0.00FY 2019$0.00FY 2020$0.00FY 2021$0.00FY 2022$0.00FY 2023$0.00FY 2024$53.9MFY 2025$67.5M
$0$67.5M

Free cash flow by year

2016 → 2025

FY 2016$-25.3MFY 2017$-28.4MFY 2018$-48.7MFY 2019$-54.8MFY 2020$-72.0MFY 2021$-105.7MFY 2022$-110.7MFY 2023$-125.0MFY 2024$133.8MFY 2025$-70.7M
-$25.3M-$70.7M

Gross margin by year

2024 → 2025

FY 2024100.0%FY 202599.9%
100.0%99.9%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

5

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 12, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $834K · 10b5-1 PlanLeoni Mollie · Chief Medical Officer · $834.3KJun 22, 2026Filing
  • 8-K eventEquity Incentive Plan AmendmentJun 4, 2026Filing
  • Insider sellInsider Sell $110K · 10b5-1 PlanPowl Brian T. · Chief Commercial Officer · $110KMay 22, 2026Filing
  • Insider sellInsider Sell $21K · 10b5-1 PlanBair Teresa Brophy · Chief Legal Officer · $21.2KMay 20, 2026Filing
  • Insider sellInsider Sell $20K · 10b5-1 PlanFORD KATHLEEN · Chief Operating Officer · $20.5KMay 20, 2026Filing
  • Insider sellInsider Sell $3K · 10b5-1 PlanPowl Brian T. · Chief Commercial Officer · $3.1KMay 20, 2026Filing
  • 8-K eventEarnings ReleaseMay 12, 2026Filing
  • Quarterly report10-Q FiledMay 12, 2026Filing

Questions

Frequently asked questions

What is Kura Oncology, Inc.'s market cap?

Kura Oncology, Inc. (KURA) has a market capitalization of $900.2M.

What is KURA's P/E ratio?

A meaningful P/E ratio is not available for KURA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is KURA's price-to-book (P/B) ratio?

KURA trades at 5.17 times book value per share.

Are insiders buying KURA stock?

SEC Form 4 filings show no open-market insider buys at Kura Oncology, Inc. in the last 90 days (5 sells).

Same arena

Related companies in Biotechnology

JANX

Janux Therapeutics, Inc.

$894.3M

SPRY

ARS Pharmaceuticals, Inc.

$908.6M

XNCR

Xencor, Inc.

$885.3M

ABUS

Arbutus Biopharma Corporation

$922.5M

PHAR

Pharming Group N.V.

$942.8M

MGTX

MeiraGTx Holdings plc

$962.2M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.